Lilly ICOS Cialis sales exceed $200M

Lilly ICOS, the joint venture between ICOS and Eli Lilly which is marketing Cialis (tadalafil) for the treatment of erectile dysfunction, says that, for the year ended December 31, 2003, it made a net loss of $174.7 million, compared to $131.3 million for 2002.

In its first year on the market, 2003 worldwide net product sales of Cialis totaled $203.3 million, of which $129.8 million represent sales in Lilly ICOS joint-venture territories and $73.5 million turnover in Lilly-only markets. Total Lilly ICOS revenues were $144.5 million, including $14.7 million in royalties on Cialis sales reported by Lilly.

The firm says that Cialis has captured a significant share of ED sales in Europe: 35% in France, 30% in Germany, 27% in Italy and 16% in both Spain and the UK. Moreover, it claims, this share had increased to 22% in Italy and 40% in Germany through November 2003, it added.